Omrčen Tomislav
Department of Oncology and Radiotherapy, University Hospital of Split, School of Medicine, University of Split.
Acta Clin Croat. 2019 Nov;58(Suppl 2):69-72. doi: 10.20471/acc.2019.58.s2.11.
Treatment with androgen deprivation (ADT) has for many years been a standard treatment for patients with metastatic hormone-sensitive prostate cancer (mHSPC). However, several phase 3 randomized trials have completely changed the therapeutic approach for these patients. First, two phase 3 trials, CHAARTED and STAMPEDE, showed that docetaxel added to ADT improves survival of patients with mHSPC. Here we present an overview of the most important trials in this setting: STAMPEDE, LATITUDE, ARCHES, ENZAMET and TITAN in which abiraterone acetate, enzalutamide and apalutamide combined with ADT achieved significant improvement in overall survival of patients with mHSPC compared with ADT only. All three agents combined with ADT became new standard of therapy for this group of patients.
多年来，雄激素剥夺疗法（ADT）一直是转移性激素敏感性前列腺癌（mHSPC）患者的标准治疗方法。然而，几项3期随机试验彻底改变了这些患者的治疗方法。首先，两项3期试验CHAARTED和STAMPEDE表明，在ADT基础上加用多西他赛可提高mHSPC患者的生存率。在此，我们概述了该领域最重要的试验：STAMPEDE、LATITUDE、ARCHES、ENZAMET和TITAN，其中醋酸阿比特龙、恩杂鲁胺和阿帕他胺与ADT联合使用，与单纯ADT相比，显著提高了mHSPC患者的总生存率。这三种药物与ADT联合使用均成为这类患者的新治疗标准。
